1. Obravnava ambulantnih bolnikov z ishemijo pri perfuzijski scintigrafiji srcaKristina Arih, Jonas Podnar, Barbara Gužič-Salobir, Monika Štalc, 2025, izvirni znanstveni članek Povzetek: Izhodišče: Ishemija srčne mišice je kompleksno dogajanje, ki pomeni za bolnika slabši izid. Perfuzijska scintigrafija srca (PSM) je neinvazivna metoda, s katero ugotavljamo prisotnost ishemije. Namen naše raziskave je bil pridobiti podatke o obravnavi bolnikov z ugotovljeno ishemijo pri PSM, saj le-teh v slovenskem prostoru doslej nismo imeli na voljo.Metode: V raziskavo smo vključili 306 ambulantno obravnavanih bolnikov, ki so jim v letu 2020 pri PSM ugotovili ishemijo. Iz baze podatkov Klinike za nuklearno medicino in iz informacijskih sistemov smo zbrali demografske, klinične in scinti-grafske podatke ter podatke o napotitvi na koronarografijo in podatke o revaskularizacijskih posegih.Rezultati: Na koronarografijo so napotili 74 % bolnikov, ki so imeli značilno več tipične prsne bolečine (40 % vs. 23 %, p=0,005) in dispneje (50 % vs. 38 %, p=0,051) kot nenapoteni bolniki. Na koronarografijo so napotili značilno več bolnikov z zmerno in hudo ishemijo kot pa bolnikov z blago ishemijo (83 % vs. 65 %, p=0,003; 93 % vs. 65 %, p<0,001) ter več bolnikov s hudo ishemijo kot tistih z zmerno ishemijo (93 % vs. 83 %, p=0,003). Pri večjem deležu bolnikov z obsegom ishemije nad 10 % je bil nato opravljen revaskularizacijski poseg (84 % vs. 61 %, p=0,036).Zaključek: Zdravniki večino bolnikov z ishemijo pri PSM napotijo na koronarografijo. Obseg ishemije je povezan z napoti-tvijo na koronarografijo in odločitvijo za revaskularizacijske posege.
Ključne besede: ishemija, perfuzijska scintigrafija srca, koronarografija, obstruktivna koronarna bolezen, revaskularizacija
Objavljeno v DiRROS: 20.03.2026; Ogledov: 221; Prenosov: 138
 Celotno besedilo (890,09 KB)
Gradivo ima več datotek! Več... |
2. Emerging therapies and new directions in the treatment of pulmonary arterial hypertensionGrzegorz Kopec, Andris Skride, Egle Ereminiene, Iveta Šimkova, Roxana Enache, Miroslav Samaržija, Barbara Salobir, Pavel Jansa, 2025, pregledni znanstveni članek Povzetek: Pulmonary arterial hypertension (PAH) is a severe and progressive disease with limited survival prospects under currently available therapies. Since the 2022 edition of the European Society of Cardiology and European Respiratory Society guidelines on pulmonary hypertension, substantial clinical evidence has emerged, supporting a new treatment algorithm for PAH as presented at the 7th World Symposium on Pulmonary Hypertension 2024 and the following proceeding papers. Key updates include the introduction of sotatercept as a second-line therapy leading to a revised definition of maximal medical therapy now encompassing agents from four therapeutic groups (phosphodiesterase-5 inhibitors/soluble guanylate cyclase stimulators, endothelin receptor antagonists, prostacyclin pathway agents, and sotatercept), instead of three (phosphodiesterase-5 inhibitors/soluble guanylate cyclase stimulators, endothelin receptor antagonists, prostacyclin pathway agents). Other novelties include the elimination of a distinct pathway for patients with cardiopulmonary comorbidities in favor of an individualized approach, a reduction in the initial patient assessment risk categories from three to two, and a follow-up interval shortened from 3–6 months to 3–4 months post-treatment initiation. This review presents these advancements and emphasizes the need for their widespread implementation in clinical practice. At the end, we present new opportunities and challenges in the treatment of pulmonary arterial hypertension in eight Central and Eastern European countries.
Ključne besede: activin signaling inhibitors, novel therapies, risk assessment, treatment strategy, sotatercept
Objavljeno v DiRROS: 15.12.2025; Ogledov: 402; Prenosov: 651
Celotno besedilo (175,71 KB)
Gradivo ima več datotek! Več... |
3. Long-term treatment with subcutaneous treprostinil in patients with severe inoperable chronic thromboembolic pulmonary hypertension in the multimodal therapy era (data from CTREPH study open label extension)Pavel Jansa, Roela Sadushi-Kolici, Nika Skoro-Sajer, Grzegorz Kopec, Iveta Šimkova, Regina Steringer-Mascherbauer, Barbara Salobir, 2025, izvirni znanstveni članek Povzetek: The aim of the open label extension (OLE) of CTREPH study was to characterize multimodal treatment in patients with severe inoperable CTEPH, to describe long-term subcutaneous (SC) treprostinil safety and tolerability, and to evaluate change in functional class and exercise capacity over 24 months since completion of the blinded phase of CTREPH. The target population in the OLE consisted of patients who completed 24 weeks of blinded treatment with either high-dose treprostinil of around 30 ng/kg/min (former high-dose group), or low-dose treprostinil of around 3 ng/kg/min (former low-dose group) in the CTREPH study. From the start of OLE, treprostinil dose and any additional therapy were chosen according to the standard of care and physician's discretion. Out of 47 enrolled patients, 20 patients received other PH drugs during OLE and 17 patients underwent at least 1 BPA session. Number of treprostinil-related AEs was substantially higher in the former low-dose group in comparison to the former high-dose group. Related AEs were also more frequent during the first 6 months of the preceding blinded trial than over 24 months of OLE, especially infusion site pain and all local infusion site reactions. No new safety signal was detected. Evaluated clinical outcomes show sustained benefit from long-term treprostinil treatment. Long-term SC treprostinil is a safe and effective component of multimodal treatment for patients with severe CTEPH. Patients who tolerate treprostinil after initiation are likely to continue tolerating it over time, with the clinical benefit maintained over 24 months.
Ključne besede: chronic thromboembolic pulmonary hypertension, multimodal treatment, subcutaneous treprostinil
Objavljeno v DiRROS: 15.12.2025; Ogledov: 1034; Prenosov: 242
Celotno besedilo (693,79 KB)
Gradivo ima več datotek! Več... |
4. Case report : congenital extrahepatic portocaval shunt presenting as pulmonary arterial hypertension in a pregnant patientMatevž Harlander, Maja Badovinac, Frosina Markoska, Barbara Salobir, Tomaž Štupnik, Marija Dolenšek, Izidor Kern, Vojka Gorjup, Nazzareno Galiè, 2022, drugi znanstveni članki Povzetek: Congenital extrahepatic portocaval shunt (CEPS) is a rare condition in which a rare congenital vascular anomaly of the portal system is present. CEPS may manifest as pulmonary arterial hypertension (PAH). When diagnosed and treated early, PAH can be reversible. We report a case of a previously asymptomatic woman, who manifested with severe pulmonary hypertension during pregnancy and was consequently diagnosed with CEPS. After unsuccessful medical treatment, urgent lung transplantation was done.
Ključne besede: pulmonary hypertension, pregnancy, congenital extrahepatic portocaval shunt, Abernethy malformation, pulmonary arterial hypertension
Objavljeno v DiRROS: 10.01.2022; Ogledov: 1925; Prenosov: 1374
Celotno besedilo (883,93 KB)
Gradivo ima več datotek! Več... |
5. |
6. |
